Hyaluronic acid-coated solid lipid nanoparticles enhance antirheumatic activity and reduce toxicity of methotrexate.
Yashika MirchandaniVandana B PatravaleBrijesh SPublished in: Nanomedicine (London, England) (2022)
Aim: Methotrexate (MTX) is used to treat rheumatoid arthritis (RA) but is associated with severe toxicity. To minimize these side effects of MTX, the study was undertaken to explore its delivery using solid lipid nanoparticles (SLNs). Materials & methods: MTX-loaded SLNs were synthesized and coated with hyaluronic acid (HA) for targeted drug delivery and evaluated for their safety and efficacy in a complete Freund's adjuvant (CFA) model. Results: HA-MTX-SLNs (230.0 ± 46.4 nm) with 78.75% entrapment were developed and showed sustained drug release with a significant reduction in toxicity and enhanced activity of the drug at the targeted site upon oral administration in CFA-induced rats. Conclusion: HA-MTX-SLNs can be considered as an efficient therapeutic agents for the treatment of RA.
Keyphrases
- hyaluronic acid
- rheumatoid arthritis
- drug delivery
- drug release
- cancer therapy
- disease activity
- oxidative stress
- ankylosing spondylitis
- high dose
- oxide nanoparticles
- interstitial lung disease
- drug induced
- fatty acid
- rheumatoid arthritis patients
- diabetic rats
- photodynamic therapy
- systemic lupus erythematosus
- low dose